Literature DB >> 23949726

Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention.

Kazuhiro Saito1, Joseph Ledsam, Steven Sourbron, Tsuyoshi Hashimoto, Yoichi Araki, Soichi Akata, Koichi Tokuuye.   

Abstract

OBJECTIVE: To investigate if tracer kinetic modelling of low temporal resolution dynamic contrast-enhanced (DCE) MRI with Gd-EOB-DTPA could replace technetium-99 m galactosyl human serum albumin (GSA) single positron emission computed tomography (SPECT) and indocyanine green (ICG) retention for the measurement of liver functional reserve.
METHODS: Twenty eight patients awaiting liver resection for various cancers were included in this retrospective study that was approved by the institutional review board. The Gd-EOB-DTPA MRI sequence acquired five images: unenhanced, double arterial phase, portal phase, and 4 min after injection. Intracellular contrast uptake rate (UR) and extracellular volume (Ve) were calculated from DCE-MRI, along with the ratio of GSA radioactivity of liver to heart-plus-liver and per cent of cumulative uptake from 15-16 min (LHL15 and LU15, respectively) from GSA-scintigraphy. ICG retention at 15 min, Child-Pugh cirrhosis score (CPS) and postoperative Inuyama fibrosis criteria were also recorded. Statistical analysis was with Spearman rank correlation analysis.
RESULTS: Comparing MRI parameters with the reference methods, significant correlations were obtained for UR and LHL15, LU15, ICG15 (all 0.4-0.6, P < 0.05); UR and CPS (-0.64, P < 0.001); Ve and Inuyama (0.44, P < 0.05).
CONCLUSION: Measures of liver function obtained by routine Gd-EOB-DTPA DCE-MRI with tracer kinetic modelling may provide a suitable method for the evaluation of liver functional reserve. KEY POINTS: • Magnetic resonance imaging (MRI) provides new methods of measuring hepatic functional reserve. • DCE-MRI with Gd-EOB-DTPA offers the possibility of replacing scintigraphy. • The analysis method can be used for preoperative liver function evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949726     DOI: 10.1007/s00330-013-2983-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  49 in total

1.  Timing bolus dynamic contrast-enhanced (DCE) MRI assessment of hepatic perfusion: Initial experience.

Authors:  Simon Baxter; Zhen J Wang; Bonnie N Joe; Aliya Qayyum; Bachir Taouli; Benjamin M Yeh
Journal:  J Magn Reson Imaging       Date:  2009-06       Impact factor: 4.813

2.  Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system.

Authors:  D R Vera; K A Krohn; P O Scheibe; R C Stadalnik
Journal:  IEEE Trans Biomed Eng       Date:  1985-05       Impact factor: 4.538

3.  Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI.

Authors:  Henrik Nilsson; Lennart Blomqvist; Lena Douglas; Anders Nordell; Eduard Jonas
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

4.  Preoperative assessment of residual hepatic functional reserve using 99mTc-DTPA-galactosyl-human serum albumin dynamic SPECT.

Authors:  E H Hwang; J Taki; N Shuke; K Nakajima; S Kinuya; S Konishi; T Michigishi; T Aburano; N Tonami
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

5.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Comparison of Tc-99m-GSA scintigraphy with hepatic fibrosis and regeneration in patients with hepatectomy.

Authors:  Toshihiro Iguchi; Shuhei Sato; Yoshihiro Kouno; Yoshihiro Okumura; Shiro Akaki; Toshihide Tsuda; Keita Kobayashi; Susumu Kanazawa; Yoshio Hiraki
Journal:  Ann Nucl Med       Date:  2003-05       Impact factor: 2.668

8.  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA.

Authors:  Hun-Kyu Ryeom; Seong-Hun Kim; Jong-Yeol Kim; Hye-Jeong Kim; Jong-Min Lee; Yong-Min Chang; Yong-Sun Kim; Duk-Sik Kang
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

9.  A new liver functional study using Tc-99m DTPA-galactosyl human serum albumin: evaluation of the validity of several functional parameters.

Authors:  K Koizumi; G Uchiyama; T Arai; T Ainoda; Y Yoda
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

10.  A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics.

Authors:  Eric Nguyen-Khac; Céline Lobry; Denis Chatelain; David Fuks; Jean Paul Joly; Marie Brevet; Blaise Tramier; Charlotte Mouly; Vincent Hautefeuille; Bruno Chauffert; Jean Marc Regimbeau
Journal:  Int J Hepatol       Date:  2013-03-07
View more
  13 in total

1.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

2.  Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.

Authors:  N Verloh; M Haimerl; F Zeman; M Schlabeck; A Barreiros; M Loss; A G Schreyer; C Stroszczynski; C Fellner; P Wiggermann
Journal:  Eur Radiol       Date:  2014-02-16       Impact factor: 5.315

3.  Enhancement of the low resolution image quality using randomly sampled data for multi-slice MR imaging.

Authors:  Yong Pang; Baiying Yu; Xiaoliang Zhang
Journal:  Quant Imaging Med Surg       Date:  2014-04

4.  A New Model for MR Evaluation of Liver Function with Gadoxetic Acid, Including Both Uptake and Excretion.

Authors:  Daniel Truhn; Christiane K Kuhl; Alexander Ciritsis; Alexandra Barabasch; Nils A Kraemer
Journal:  Eur Radiol       Date:  2018-06-15       Impact factor: 5.315

5.  Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC.

Authors:  Mengqi Huang; Shunli Shen; Huasong Cai; Zhenpeng Peng; Wan Hang Keith Chiu; Zi-Ping Li; Baogang Peng; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

6.  Assessing liver function in patients with HBV-related HCC: a comparison of T₁ mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI.

Authors:  Ying Ding; Sheng-Xiang Rao; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-12-19       Impact factor: 5.315

7.  Hepatic clearance measured with (99m)Tc-GSA single-photon emission computed tomography to estimate liver fibrosis.

Authors:  Masahiko Taniguchi; Atsutaka Okizaki; Kenji Watanabe; Koji Imai; Koichiro Uchida; Takahiro Einama; Noriyuki Shuke; Naoyuki Miyokawa; Hiroyuki Furukawa
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

8.  Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.

Authors:  Ying Ding; Shengxiang Rao; Li Yang; Caizhong Chen; Mengsu Zeng
Journal:  Radiol Med       Date:  2016-07-23       Impact factor: 3.469

Review 9.  Current Modalities for the Assessment of Future Remnant Liver Function.

Authors:  Fadi Rassam; Pim B Olthof; Roelof J Bennink; Thomas M van Gulik
Journal:  Visc Med       Date:  2017-11-30

Review 10.  Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Yuling Yan; Xilin Sun; Baozhong Shen
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.